Month: May 2025

Great Elm Capital Corp. Announces First Quarter 2025 Financial Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Company to Host Conference Call and Webcast at 8:30 AM ET on May 6, 2025 PALM BEACH GARDENS, Fla., May 05, 2025 (GLOBE NEWSWIRE) — Great Elm Capital Corp. (“we,” “our,” the “Company” or “GECC”) (NASDAQ: GECC), a business development company, today announced its financial results for the first quarter ended March 31, 2025. First Quarter and Other Recent HighlightsGECC increased its quarterly distribution by 5.7% for the first quarter of 2025 to $0.37 per share, from $0.35 per share, which was paid on March 31, 2025.The Board of Directors approved a quarterly dividend of $0.37 per share for the second quarter of 2025, equating to a 14.7% annualized yield on GECC’s May 2, 2025 closing price of $10.09.Total investment income (“TII”) for the quarter ended March 31, 2025 was a record $12.5 million.Highest cash income...

Fabrinet Announces Third Quarter Fiscal Year 2025 Financial Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Record Third Quarter Revenue Exceeds Guidance RangeBANGKOK, May 05, 2025 (GLOBE NEWSWIRE) — Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced its financial results for its third fiscal quarter ended March 28, 2025. Seamus Grady, Chief Executive Officer of Fabrinet, said, “We had a very strong third quarter with revenue of $872 million dollars, which was above our guidance range. We delivered another strong telecom performance with growth that more than offset an anticipated sequential decline in datacom revenue. Our team continued to execute very well, producing non-GAAP EPS that also exceeded our guidance. Looking ahead, we remain optimistic and confident...

Certara Reports First Quarter 2025 Financial Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights:Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%.Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%. Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%.Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in the first quarter of 2024. Adjusted EBITDA was $34.8 million, compared to $29.1 million in the first quarter...

FreightCar America, Inc. Reports First Quarter 2025 Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Gross Profit Increased 26% with Gross Margin Expanding 780 Basis Points Generates Quarterly Operating Cash Flow of $13 million and Adjusted Free Cash Flow of $12 million Strong Order Intake Supports Reaffirmed Full Year Guidance CHICAGO, May 05, 2025 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 HighlightsRevenues of $96.3 million, consistent with expectations, decreased 40.2% from $161.1 million in the first quarter of 2024, with planned railcar deliveries of 710 units compared to 1,223 units in the prior-year period Gross margin of 14.9% with gross profit of $14.4 million, compared to gross...

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of June Initial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025 Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator Authorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway through year-end 2027SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “Our lead program, rosnilimab,...

Palomar Holdings, Inc. Reports First Quarter 2025 Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

LA JOLLA, Calif., May 05, 2025 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or “Company”) reported net income of $42.9 million, or $1.57 per diluted share, for the first quarter of 2025 compared to net income of $26.4 million, or $1.04 per diluted share, for the first quarter of 2024. Adjusted net income(1) was $51.3 million, or $1.87 per diluted share, for the first quarter of 2025 as compared to $27.8 million, or $1.09 per diluted share, for the first quarter of 2024. First Quarter 2025 HighlightsGross written premiums increased by 20.1% to $442.2 million compared to $368.1 million in the first quarter of 2024 Net income of $42.9 million compared to $26.4 million in the first quarter of 2024 Adjusted net income(1) increased 84.6% to $51.3 million compared to $27.8 million in the first quarter of 2024 Total...

SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Achieved ~25% worldwide revenue growth and positive adjusted EBITDA First Quarter 2025 Financial Highlights (all comparisons are to the prior year period)Worldwide revenue of $47.3 million, representing growth of 24.9% U.S. revenue of $44.8 million, representing growth of 26.6% Gross margin of 79.7%, representing an improvement of 80 basis points Net loss of $6.5 million, representing an improvement of 40.0% Positive adjusted EBITDA of $0.5 million $144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 millionRecent Operational Highlights (any comparisons are to the prior year period)Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective October...

Castle Biosciences Reports First Quarter 2025 Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. “We are pleased with the exceptional start to the year, marked by continued growth in test report volume and revenue in the first quarter,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We believe our ongoing success reflects...

Castle Biosciences to Acquire Previse

Written by Customer Service on May 5, 2025. Posted in Mergers And Acquisitions.

Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed. “This proposed transaction underscores our commitment to the gastrointestinal (GI) community-providers and patients,” said Derek Maetzold, president and chief executive officer of Castle Biosciences....

ThredUp Announces First Quarter 2025 Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

All results reported are for continuing operations, unless otherwise noted.Record quarterly revenue of $71.3 million, representing an increase of 10% year-over-year Quarterly gross margin of 79.1% and an increase in gross profit of 9% year-over-year Active Buyers of 1.37 million, representing growth of 6% year-over-year, with new buyer growth of 95% year-over-year, reflecting ThredUp’s best quarter for new buyer acquisition in its history Ended the quarter with cash, restricted cash, and investments of $55.4 million, up $2.6 million dollars from the previous quarter Issued a revised full year 2025 financial outlook, raising expectations for Revenue and Adjusted EBITDA marginOAKLAND, Calif., May 05, 2025 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes,...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals